ADVFN Logo ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Registrieren

Bereits Mitglied? Einloggen

Pepperstone

Jetzt Handeln

Pepperstone
Marktdaten
News
Werkzeuge
Märkte
Entdecken

Hot Features

Follow Feed

Vernetzen Sie sich mit Händlern und Investoren in unserer Follow-Feed-Community.

Optionen-Flow

Erkunden Sie umfassende Optionsdaten und nutzen Sie erweiterte Filter mit Options Flow.

Watchlist

Organisieren und überwachen Sie Ihre Aktien- und Vermögensbeobachtungsliste mit dem Monitor.
Anmelden Premium IconPremium Help Menu
DAX
18.704,42
-0,11%
S&P 500
5.303,27
0,12%
Dow Jones
40.003,59
0,34%
Euro vs US Dollar
1,0874
-0,15%
Bitcoin
66.590,36
-0,53%
Registration Strip Icon for charts Registrieren Sie sich für Echtzeit-Charts, Analysetools und Preise.
Registrieren
  1. Startseite
  2. Investieren
  3. Aktien
  4. USA
  5. NASDAQ
  6. Supernus Pharmaceuticals Inc (SUPN)

  7. Supernus Pharmaceuticals Inc (SUPN) News

SUPN

Supernus Pharmaceuticals (SUPN)

Supernus Pharmaceuticals Inc
Von:
Sortieren nach:
 Showing the most relevant articles for your search:NASDAQ:SUPN
DatumZeitQuelleÜberschriftSymbolFirma
09/05/202422h09Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:SUPNSupernus Pharmaceuticals Inc
09/05/202422h05GlobeNewswire Inc.Supernus Pharmaceuticals to Host Webcast to Review Interim Data from Ongoing Open-Label Phase IIa Study of SPN-817 for Treatment-Resistant SeizuresNASDAQ:SUPNSupernus Pharmaceuticals Inc
08/05/202422h11Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:SUPNSupernus Pharmaceuticals Inc
08/05/202422h11Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:SUPNSupernus Pharmaceuticals Inc
08/05/202422h08Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:SUPNSupernus Pharmaceuticals Inc
08/05/202422h05GlobeNewswire Inc.Supernus Announces First Quarter 2024 Financial ResultsNASDAQ:SUPNSupernus Pharmaceuticals Inc
07/05/202416h00PR Newswire (US)M8 Pharmaceuticals, an Acino company, signs an exclusive licensing agreement with Supernus for Qelbree® (Viloxazine XR) in Latin AmericaNASDAQ:SUPNSupernus Pharmaceuticals Inc
01/05/202414h00GlobeNewswire Inc.Busy Philipps Shines Spotlight on ADHD in Women and Shares her Qelbree StoryNASDAQ:SUPNSupernus Pharmaceuticals Inc
24/04/202422h05GlobeNewswire Inc.Supernus Pharmaceuticals to Announce First Quarter 2024 Financial Results and Host Conference Call on May 8, 2024NASDAQ:SUPNSupernus Pharmaceuticals Inc
08/04/202414h00GlobeNewswire Inc.Supernus Provides Regulatory Update for SPN-830NASDAQ:SUPNSupernus Pharmaceuticals Inc
06/03/202422h30GlobeNewswire Inc.Supernus to Participate in Two Upcoming Investor ConferencesNASDAQ:SUPNSupernus Pharmaceuticals Inc
29/02/202423h01Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:SUPNSupernus Pharmaceuticals Inc
29/02/202423h00Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:SUPNSupernus Pharmaceuticals Inc
28/02/202423h01Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:SUPNSupernus Pharmaceuticals Inc
28/02/202423h00Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:SUPNSupernus Pharmaceuticals Inc
28/02/202422h30GlobeNewswire Inc.Supernus to Participate in the TD Cowen 44th Annual Healthcare ConferenceNASDAQ:SUPNSupernus Pharmaceuticals Inc
27/02/202423h04Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:SUPNSupernus Pharmaceuticals Inc
27/02/202423h03Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:SUPNSupernus Pharmaceuticals Inc
27/02/202423h02Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:SUPNSupernus Pharmaceuticals Inc
27/02/202423h00Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:SUPNSupernus Pharmaceuticals Inc
27/02/202423h00Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:SUPNSupernus Pharmaceuticals Inc
27/02/202422h14Edgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NASDAQ:SUPNSupernus Pharmaceuticals Inc
27/02/202422h05GlobeNewswire Inc.Supernus Announces Fourth Quarter and Full Year 2023 Financial ResultsNASDAQ:SUPNSupernus Pharmaceuticals Inc
26/02/202423h02Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:SUPNSupernus Pharmaceuticals Inc
26/02/202423h02Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:SUPNSupernus Pharmaceuticals Inc
26/02/202423h02Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:SUPNSupernus Pharmaceuticals Inc
26/02/202423h01Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:SUPNSupernus Pharmaceuticals Inc
26/02/202423h01Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:SUPNSupernus Pharmaceuticals Inc
26/02/202423h01Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:SUPNSupernus Pharmaceuticals Inc
26/02/202423h00Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:SUPNSupernus Pharmaceuticals Inc
 Showing the most relevant articles for your search:NASDAQ:SUPN

Kürzlich von Ihnen besucht

BIT
UC8FRA
Unicredit Bank
TG
EAI
Groupe Bruxelles Lambert
COIN
RDPXETH
Dopex Rebate Token
EU
XS2101336316
ABN AMRO Bank N.V. 0.375...
GATE
WEARUSDT
Metawear
EU
L223S
L223S
TSXV
NQ
Northquest Ltd.
EU
A886T
A886T
BIT
XDWM
Xtrackers Msci World Mat...
COIN
SABRUSD
DBI
I8NC
WKN A30B24
BIT
I05671
Banca IMI
BIT
UC63FH
Unicredit Bank
BOV
ABEVT17
ABEVT17 Ex:16,38
BOV
PETRF2
PETRF2 Ex:23,95
USOTC
IGRMF
Integrum AB (GM)
Delayed Upgrade Clock
ADVFN Logo

Deutschland
Unternehmen
Geschäft
Popular
App herunterladen

Support: +44 (0) 203 8794 460 | support@advfn.de

Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen

© 2024 ADVFN PLC - Alle Rechte vorbehalten